Exabis Library
Welcome to the e-CCO Library!
DOP77: Is durable remission achievable after ileocolic resection for Crohn's disease ? Long-term results of a prospective multicentric cohort study of the GETAID Chirurgie
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP77: Is durable remission achievable after ileocolic resection for Crohn’s disease ? Long-term results of a prospective multicentric cohort study of the GETAID Chirurgie
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP77: Mesenchymal stem cell therapy for refractory Crohn’s perianal fistulas: a case series
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP77: The effectiveness of combination therapy mesenchymal stromal cells and certolizumab pegol in perianal lesions in Crohn's disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP77: Ustekinumab is associated with better effectiveness outcomes when compared to vedolizumab in Crohn's Disease patients with prior anti-TNF failure: Comparative effectiveness study from the ICC Registry
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP78 Intestinal surgery rates in ulcerative colitis and Crohn’s disease in the era of biologics: A Danish Nationwide Register Study from 2003 to 2016
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP78: Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP78: Does KONO-S anastomosis reduce recurrence in Crohn's disease compared to conventional ileocolonic anastomosis ? A nationwide propensity score-matched study from GETAID Chirurgie Group (KoCoRICCO study).
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP78: Does KONO-S anastomosis reduce recurrence in Crohn's disease compared to conventional ileocolonic anastomosis ? A nationwide propensity score-matched study from GETAID Chirurgie Group (KoCoRICCO study).
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP78: Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North study
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP78: Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multi-centre observational study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP78: Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multicenter observational study
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP78: Intestinal surgery rates in Ulcerative Colitis and Crohn’s Disease in the era of biologics – A Danish Nationwide Register Study from 2003-2016
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP78: Intestinal surgery rates in Ulcerative Colitis and Crohn’s Disease in the era of biologics – A Danish Nationwide Register Study from 2003-2016
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP78: The differential diagnosis and clinicopathological spectrum of Inflammatory Bowel Disease: An interesting and informative ECCO topical review
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: Data from the randomised CELEST study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP79: Alternative polygenic forms of Inflammatory Bowel Disease are not captured by current generations of polygenic risk scores
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP79: Alternative polygenic forms of Inflammatory Bowel Disease are not captured by current generations of polygenic risk scores
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP79: Biomarkers for IBD using OLINK Proteomics inflammation panel: Preliminary results from the COLLIBRI consortium
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP79: Dose escalation of upadacitinib in Crohn’s Disease patients with inadequate response: Data from the randomised CELEST study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM